Denali Therapeutics Inc.

As of June 30, 2026, Denali Therapeutics Inc. carries a market capitalization of 3.60B, placing it among publicly traded companies globally. Its enterprise value stands at 3.00B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Denali Therapeutics Inc.'s next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, Denali Therapeutics Inc. has 159.76M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1,288.26, and the price-to-book ratio stands at 4.92.

These figures are as of June 30, 2026. The EV/Sales ratio of 952.27 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 3.00B versus a market cap of 3.60B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Denali Therapeutics Inc. maintains a current ratio of 8.37, meaning it holds 8.4x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Denali Therapeutics Inc. posted a negative return on equity (ROE) of -54.93, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -44.01, reflecting losses generated across the asset base. The company generates approximately 6,534.61 in revenue per employee across its workforce of 482.75, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Denali Therapeutics Inc.'s stock has gained approximately 20.35% over the past 52 weeks. The 50-day moving average sits at 18.60, while the 200-day moving average is 18.39.

Over the twelve months ended June 30, 2026, Denali Therapeutics Inc. generated 3.15M in revenue and converted that into -447.67M in net income, yielding earnings per share of -2.48. EBITDA reached -461.12M, while operating income came in at -475.02M.

As of June 30, 2026, Denali Therapeutics Inc. holds 621.88M in cash and equivalents against 28.19M in total debt, resulting in a net debt position of -176.40M. Total book value stands at 731.03M, with working capital of 581.06M providing operational flexibility.

Denali Therapeutics Inc. produced -379.92M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -2.99M in capital expenditures, free cash flow totaled -382.91M - equivalent to -2.12 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -15,058.19 and net profit margin of -14,191.20 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -9.42: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -10.35, meaning Denali Therapeutics Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Denali Therapeutics Inc. has an Altman Z-Score of 3.88, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.